| Literature DB >> 32832139 |
Agnieszka Dyrda1, Alfonso Anton1,2, Juan Pablo Figueroa-Vercellino3, Marta Pazos3.
Abstract
PURPOSE: To present long-term results of modified bleb-limiting conjunctivoplasty as a successful treatment for intractable bleb dysesthesia and to review the literature on the surgical management of dysesthetic bleb.Entities:
Year: 2020 PMID: 32832139 PMCID: PMC7424410 DOI: 10.1155/2020/7570454
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Demographic characteristics, dysesthetic bleb characteristics, and surgical outcomes of series of consecutive cases.
| Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
|
| ||||
| Sex/age | M/69 | M/69 | F/72 | F/81 |
| Type of glaucoma | POAG | POAG | POAG | POAG |
| IOP (mmHg) | 21 | 17 | 18 | 16 |
| Topical treatment | PG + | PG + | PG + CAI + | PG + |
| BCVA | 20/50 | 20/32 | 20/40 | 20/40 |
| Primary procedure | PT + MMC | PT + MMC | PT + MMC | PT + MMC |
| Additional treatment | LSL#3 + 5FU#7 | LSL#1 + 5FU#2 | LSL#1 + 5FU#1 | No |
| BCVA | 20/25 | 20/25 | 20/40 | 20/40 |
| IOP (mmHg) | 9 | 10 | 6 | 12 |
| VCDR | 0.85 | 0.95 | 0.9 | 0.8 |
| OCT | 50 | 47 | 52 | 54 |
| VF-MD (dB) | −16.75 | −23.3 | −30.44 | −28.10 |
|
| ||||
|
| ||||
| Elapsed time (mo) from primary surgery | 13 | 11 | 4 | 9 |
| IBAGS | 2(H) × 3(E) | 2(H) × 3(E) | 3(H) × 3(E) | 3(H) × 3(E) |
| Extension | 110° | 180° | 200° | 180° |
| Signs | Red eye | Red eye | Red eye Dellen | Red eye Dellen |
| Symptoms | FBS | FBS | FBS | FBS |
| Lubrication topical treatment | SH 1gtt/h + C 1app/ | SH 1gtt/h + C 1app/ | SH 1gtt/h + C 1app/ | SH 1gtt/h + C 1app/ |
| Elapsed time (mo) to bleb reduction | 2 | 1 | 1.5 | 3 |
|
| ||||
|
| ||||
| Type of surgery | CP + E | CP | CP | CP + E |
| Signs/symptoms | —/— | —/— | —/— | —/— |
| IOP 24 hrs (mmHg) | 12 | 10 | 17 | 26 |
| IOP 1 mo (mmHg) | 10 | 8 | 10 | 14 |
| IOP 6 mos (mmHg) | 12 | 10 | 10 | 14 |
| IOP 12 mos (mmHg) | 12 | 10 | 10 | 14 |
| VCDR | 0.85 | 0.95 | 0.9 | 0.8 |
| OCT | 50 | 52 | 54 | 56 |
| VF-MD (dB) | −13.25 | −23.85 | −30.51 | −28.97 |
| BCVA | 20/25 | 20/25 | 20/40 | 20/40 |
M: masculine, F: feminine, POAG: primary open-angle glaucoma, IOP (mmHg): intraocular pressure (millimeters of mercury), PG: prostaglandin analogues, β: beta blocker, α: alpha adrenergic agonist, CAI: carbonic anhydrase inhibitor, BCVA: best-corrected visual acuity, PT: phaco + trabeculectomy, MMC: mitomycin C, LSL: laser suturolysis, 5FU: 5 fluorouracil, VCDR: vertical cup to disc ratio, OCT: optical coherence tomography, VF-MD(dB): visual field mean deviation (decibels), mos: months, IBAGS: Indiana Bleb Appearance Grading Scale [6], H: height, E: horizontal extent, FBS: foreign body sensation, SH 1gtt/h: sodium hyaluronate 1drop every hour, C 1app/n: carbomer 1 application every night, CP + E: conjunctivoplasty + excision of subconjunctival connective tissue, and CP: conjunctivoplasty.
Figure 1Dysesthetic bleb before surgical treatment: nasal (a–c) or temporal (d) extension, hyperemia (a, b) and Dellen (c, d). 1st month (e, f) and 12th month (g, h) after bleb-limiting conjunctivoplasty.
Figure 2Flowchart showing literature search.
Literature review of surgical management of circumferential, dysesthetic bleb after glaucoma filtering surgery.
| Study | Type | Sex | Age |
| Primary proc | Time to Sx | Type of Sx | Comp ReSx | Presx IOP | IOP 24 h | IOP 1 m | IOP 3 m | IOP 6 m | IOP 12 m | Final IOP | Success (%) | Meds | F-U |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S Begum et al. [ | Retro case series | 6F 1M | 67 (60–77) | 7 | T + MMC | 18 m | Bleb compression sutures, autologous blood | 2 needlings | 11 ± 2.7 | N/A | 11 ± 2.5 | 11.1 ± 2.5 | N/A | 12 ± 4.7 | 12 ± 4.7 | N/A | 0 | 29.4 ± 23.7 m |
| JE Morgan et al. [ | Retro case series | 5F 6M | 68 (47–78) | 11 | T | 461 d (41–2023) | Bleb compression sutures, autologous blood | 8 autologous blood | 6.7 (0–12) | 17.3 (9–25) | N/A | N/A | N/A | N/A | 11.3 (5–16) | N/A | 0 | 45 w (8–81) |
| D Faingold et al. [ | Retro rev | N/A | N/A | 4 | T + MMC/T + MMC + P | 3 ± 2 m | Transconj trab flap suturing | 2 resx, 1 leak | 4.2 ± 0.6 | N/A | N/A | N/A | N/A | N/A | 8. 7 ± 3.5 | 100% | N/A | 40.7 ± 17.5 m |
| IC l-Harazi et al. [ | Retro rev | 4F 5M | 71 (56–81) | 9 | T | Bleb window cryopexy | 1 misdirection | 13.9 (8–26) | N/A | N/A | N/A | N/A | N/A | 13.4 (10–16) | 89% | 1 | 15.5 m (5–26) | |
| R Tabet et al. [ | Retro rev | 5F 1M | 57.1 ± 12.4 | 6 | 4 T + MMC, 2 T + 5FU | 1.6 ± 1.8 y | “Bleb window”-pexy | No | 9.8 ± 4.4 | 10.33 ± 4.4 | 10.0 ± 4.7 | 9.5 ± 4.4 | 11 ± 6.2 | 12.2 ± 2 | 100% | 0 | 6.6 ± 1.7 m (3.5 to 8.3) | |
| MI Canut et al. [ | Retro case series | 3F 4M | 63 (44–78) | 7 | T + MMC, T + MMC+, NPDS + MMC + SK-gel + P, NPDS + SK-gel | 32 (24–108) m | Partial bleb excision + conj advancement | 1 filtering sx | 14.0 (8–18) | 14.8 ± 3.5 | 14.9 ± 3 | N/A | N/A | 15.6 ± 6.1 | N/A | 43% (3/7) | 4 | 43.7 ± 29.9 m |
| S Radhakrishnan et al. [ | Retro case series | 90F (54%) | 67 ± 14 | 28 | T (69%) | 3.5 ± 3.7 y | Excision of the entire bleb (22) or partial (6) with conj advancement | 3 filtering sx, 2 resx, 6 still pain, 3 other (blebitis) | 11.9 ± 4.7 | N/A | N/A | N/A | N/A | N/A | 13.4 ± 5.9 | 57% (16/28) | 3 | 2.8 ± 2.7 y |
| CC Schnyder et al. [ | Retro rev | 12F 4M | 62 ± 15.4 | 2 | 1 T MMC, 1 T | 31 ± 12.7 m | Bleb reduction and free conjunctival autologous graft | 1 needling | 10 ± 4.2 | N/A | N/A | N/A | N/A | N/A | 12 ± 2.8 | 38.3% | 0 | 23 ± 1.4 m |
| GA Lee et al. [ | Retro case series | 1M | 69 | 1 | T + MMC/5FU | N/A | Bleb revision with sliding conj flap and fibrin glue | No | 10 | N/A | N/A | N/A | N/A | N/A | 13 | 100% | 0 | 31 m |
| SE LaBorwit et al. [ | Retro case series | 18F 13M | 57 (14–82) | 11 | 8 T/3 T P | 2.8 ± 2 y | Bleb reduction (excision with conjunctiva advancement in 10 and conjunctival autograft in 1) | 5 resx | 11.5 ± 4.3 | N/A | N/A | N/A | N/A | N/A | 13.2 ± 4.6 | N/A | 0 | 18.1 ± 11.7 m |
| EJ van de Geijn et al. [ | Retro rev | 17F 1M | 59.6 (21–79) | 2 | T + MMC (75%) | 14.5 ± 12 m | Bleb excision and conjunctiva and Tenon advancement | No | 11 ± 4.2 | N/A | N/A | N/A | N/A | N/A | 11 ± 0 | 100% | 0 | 52 ± 11.3 m |
| Y Catoira et al. [ | Retro rev | 12F 18M | 45.3 ± 21 | 3 | 1 T, 1 T P, 1 T MMC | 29.1 m (3–114) | Bleb revision by conj advancement | 6.6% ptosis, 13% hypertropia | 12.7 ± 1.2 | N/A | N/A | N/A | N/A | N/A | 17 ± 3.5 | 67% | 1 | 17.3 ± 23.2 m |
| S Anis et al. [ | Retro rev | 7F 8M | 67.6 (51–81) | 15 | T + MMC/5FU | 2.6 ± 3.0 y (3 m-8.6 y) | Bleb-limiting conjunctivoplasty | 1 leak resolved spontaneously | 9.4 ± 4.7 | N/A | 9.2 ± 5.0 | 9.2 ± 5.0 | N/A | 10.2 ± 6.6 | N/A | 93.3% | 0 | >3 m |
| M Lloyd et al. [ | Retro rev | 3F 8M | 60 ± 11.0 | 13 | T + MMC | 24 w (11 w-16 m) | Bleb-limiting conjunctivoplasty with removal of subconj scar tissue | No | 10.6 ± 3.4 | N/A | 12.8 ± 5.3 | 11.8 ± 4.8 | 11.5 ± 2.7 | 12.6 ± 3.1 | N/A | 100% | 3 | >1 y |
| R Rahman et al. [ | Case series | 2F | 67 ± 5.7 | 4 | 2 T | 24 ± 17 m | Bleb-limiting conjunctivoplasty | 1 resx | 12 ± 4.4 | N/A | N/A | N/A | N/A | N/A | 14 ± 4.2 | N/A | N/A | 9.5 ± 3.5 m |
N: number of eyes included, primary proc-primary procedure, sx: surgery, Comp: complications, resx: resurgery, presx: presurgery, IOP (mmHg): intraocular pressure (millimeters of mercury), preop.: preoperatively, Meds: antiglaucoma medications, F-U: follow-up, retro: retrospective study, rev-revision, F: feminine, M: masculine, T: trabeculectomy, MMC: mitomycin C, P: phacoemulsification, 5FU: 5 fluorouracil, NPDS: nonpenetrating deep sclerectomy, d: days, w: weeks, m: months, y: years, N/A: not available. D Faingold et al. A complete success was defined as achieving a total resolution of the choroidal effusions or a total resolution of symptoms related to dysesthesia without the addition of IOP-lowering drops. IC l-Harazi et al. Success was defined as subjective relief of symptoms, adequate control of the IOP (no greater than 16 mm Hg), and restoration of filtering bleb function without further antiglaucoma medications or surgical bleb revision. R Tabet et al. Complete success was defined as complete resolution of symptoms and flattening of the interpalpebral portion of the bleb while maintaining an IOP between 8 and 20 mm Hg without further antiglaucoma medications or surgical bleb revision. MI Canut et al. Complete success defined as maintenance of individual target IOP without a second revision, surgery, or glaucoma medications. S Radhakrishnan et al. Successful outcome was defined as elimination of primary indication, no requirement for further intraocular pressure- (IOP-) lowering surgery, no major complication, and no development of new bleb-related complication. CC Schnyder et al. The complete success rate was defined by an IOP >6 mm Hg and <21 mm Hg, with a visual acuity equal to or better than the preoperative visual acuity without any glaucoma medication. GA Lee et al. A successful outcome was defined as the resolution of the presenting indication for revision, with maintenance of IOP with the same or reduced number of glaucoma medications in the absence of further glaucoma surgery. EJ van de Geijn et al. Surgical success was defined as a final intraocular pressure between 6 and 22 mm Hg with or without topical antiglaucoma medication, resolution of symptoms, and no need for repeat glaucoma surgery (except for repeat revision surgery). Y Catoira et al. Success was defined as resolution of the bleb-associated complication necessitating the revision (discomfort) with maintenance of intraocular pressure greater than or equal to 6 and less than or equal to 21 mm Hg without glaucoma medications. S Anis et al. Success criteria were defined as subjective resolution of symptoms and maintenance of IOP with no subsequent surgical intervention. M Lloyd et al. Bleb functionality defined as adequate IOP control without further surgery. The whole studied cohort.